Floatz logo

16 assets in Acute Myeloid Leukemia By FAB Classification

Therapeutic assets addressing Acute Myeloid Leukemia By FAB Classification, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Daunomycin
Acute Myeloid Leukemia By FAB Classification
Wake Forest University Health SciencesP3BBB (78)
Idarubicin
Acute Myeloid Leukemia By FAB Classification
University of NebraskaP3BB (71)
Azacitidine
Acute Myeloid Leukemia By FAB Classification
guomeiP2BB (65)
Midostaurin
Acute Myeloid Leukemia By FAB Classification
Mayo ClinicP2B (63)
Cytarabine
Acute Myeloid Leukemia By FAB Classification
University of NebraskaP2B (62)
Fludarabine
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2B (61)
Mocravimod
Acute Myeloid Leukemia By FAB Classification
Priothera SASP3B (60)
Decitabine
Acute Myeloid Leukemia By FAB Classification
University of NebraskaP2B (57)
Sirolimus
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2B (57)
Tacrolimus
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2B (57)
Venetoclax
Acute Myeloid Leukemia By FAB Classification
University Hospital, CaenP2B (57)
Gemtuzumab Ozogamicin
Acute Myeloid Leukemia By FAB Classification
National Cancer Institute (NCI)P2CCC (53)
Melphalan
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2CCC (53)
Palifermin
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2CCC (53)
wbc100 qd
Acute Myeloid Leukemia By FAB Classification
Hangzhou Weben Pharma Co., LtdP1CC (43)
sar443579
Acute Myeloid Leukemia By FAB Classification
SanofiP1/2NR ()